A new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.» Read More
The Dow and S&P fell on Wednesday after Morgan Stanley revived concerns about the health of both the banking sector and the wider economy...
Stocks staged a late rally Wednesday as investors shrugged off health-care weakness and bet on solid results from Apple after the bell.
The Lightning Round is extended in this CNBC.com exclusive feature.
Christian Andreach takes the broad view, and the first of his criteria is valuation. "What we're doing is looking for opportunities where a company's competitive position is being permanently advantaged," he told CNBC. "That is, we're seeing capacity exit certain industries, and that capacity isn't going to come back."
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift money from one to the other.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Stock and options traders are piling into Biogen Idec on speculation that the drug maker could be a takeover target. About 75,000 options contracts traded on the name, more than 10 times the average over the last 20 session...
Cramer makes the call on viewers' favorite stocks.
The cola wars are coming to an end, and Cramer has chosen a winner.
Following are the week’s biggest winners and losers. Find out why shares of AK Steel and Wynn Resorts popped while Monsanto and Capital One dropped..
"This is a really big moment," says one investment pro. "The real question in my mind is if we are dragging the floor up."
The markets surged on Wednesday following the Fed's announcement that it would buy up to $300 billion in longer-term debt. At the session high shortly after the Fed's announcement, the S&P 500 climbed back above the 800 level for the first time since February 17. The index, however, still hasn't closed above 800 since February 13. Nevertheless, by crossing the 800 mark during the day yesterday, the S&P had officially moved up over 20% from its March 6 low of 666.79.
The stock market's surprising show of strength Tuesday is convincing traders the rally still has a ways to go.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
The abrupt end of Wall Street's latest rally proves once again that short-term investing is a hazardous business, according to Sarat Sethi of Douglas C. Lane & Associates. That having been said, there are more short-term opportunities coming.
In an era that some might call corporate welfare, Cramer discusses who needs to generate their own cash.
Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.
In today’s Fast Money final call, with big deals being made in big Pharma, is this a one-sector phenomenon? Pete Najarian, co-founder of OptionMonster.com, doesn’t think so.
Retailers, fast food restaurants and consumer goods manufacturers are seeing a strong response as frugal consumers try to weather the economic downtown.
Even better: Events that could push the Dow up another 1,000 points.
The IBB biotech ETF is drawing strong options activity Thursday, as news ranging from mergers to government regulation continues to rock the sector.